Dr Paul Kelly
MBBS, MD, FRACP
Acting Chairman
Dr Paul Kelly is an Australian physician, serial entrepreneur and experienced biotechnology and life sciences executive. Dr Kelly has over 15 years experience in commercialising life science related technologies in Australia, Europe and North America. Dr Kelly is General Partner and Executive Director at OneVentures Pty Ltd, an Australian venture capital firm focused on investing in globally scalable technology businesses in the Clean Tech, New Media, IT&T and Life Sciences sectors. He has enjoyed a distinguished career as a biotechnology executive, co-founding a number of companies in the health sciences and technology arena, in Australia and US, and is a published and respected physician specialising in endocrinology. Dr Kelly has served on national governmental advisory bodies, as well as on the boards of public and private companies. He is a graduate of the University of New South Wales where he received his Bachelor of Medicine, Bachelor of Surgery (Honours), and Doctor of Medicine degrees. He is a Fellow of the Australian College of Physicians.
Dr Cliff Holloway
B.Pharm, Ph.D (Univ. Nottingham. UK)
Chief Executive Officer
Dr Cliff Holloway has over 20 years experience in the commercialisation of emerging technologies and has been instrumental in the direction and expansion of company operations and joint ventures in the US, Europe and Asia.
Following his early career in clinical research with Eli Lilly and Novartis he has since held senior and executive management positions in drug discovery platform, software technology and biopharmaceutical companies, including for Molecular Simulations (now Accelrys), Superscape and Pharmacopeia Drug Discovery Inc.
He most recently held the position of Vice President, Business Development at Arana Therapeutics (now Cephalon) with responsibility for driving the company’s commercialisation strategy through the partnering of antibody development programs and acquisition of additional assets and technologies.
Dr Angus Gidley-Baird
BSc (Hons) (ANU), PhD (Univ. Sydney)
Chief Scientific Officer
Dr Angus Gidley-Baird is responsible for Biosceptre’s commercial and scientific strategy and directs the Company’s research and development program. He has substantial senior level experience in research and commercialization of research results. Angus was a Research Director and Director of three publicly listed biomedical companies. He is an author / co-author of 39 publications in refereed scientific journals and is an inventor / co-inventor of 7 patent families. He has been a full time Research Director in biotechnology companies since 1994 and has managed the Biosceptre research and development projects since October 1999.
Terrence Caplice
Non-Executive Director
Mr Terry Caplice is a retired solicitor with extensive experience in corporate and takeover law. He has been a foundation investor and a guiding influence in the formation of numerous private and public companies. He has considerable experience as a public company director, and has in-depth knowledge of current corporate governance issues.
Gavin Currie
B Bus, M Bus and Tech, CPA
Non-Executive Director
Mr Gavin Currie is the General Manager of Creata Ventures. His role oversees the investment activities of the Creata group of companies. Prior to Creata, Gavin co-founded Arbitrage Partners, a boutique transaction services business along with SAF Capital, a private equity business. He has a background of commercial success, wide industry knowledge, and distinguishing ability to challenge the status quo while working within a participative framework. Gavin has developed a reputation for delivering value by converting synergies from previously unseen opportunities and has been employed internationally in Australia, New Zealand, England, USA and Hong Kong, with experience in cross-border transactions and investments. He holds a Bachelor of Business degree, Master of Business and Technology from the University of NSW and is a qualified CPA.
Peter Newton
Non-Executive Director
Mr Peter Newton worked for 26 years as a stockbroker, and has a record of accomplishment in public company directorships, notably in the resource sector. Peter is a former CEO of County Natwest. He is currently the Chairman of Metals X Ltd. and a director of two other Australian-based companies. He has enjoyed success in guiding investment and growth, and has substantial experience in corporate governance issues.
|
The Company 
